Efficacy and safety of apremilast in chronic cutaneous sarcoidosis

Archives of Dermatology

Volumn 148, Issue 2, 2012, Pages 262-264

  Baughman, Robert P ^a   Judson, Marc A ^b   Ingledue, Rebecca ^a   Craft, Nicole L ^b   Lower, Elyse E ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APREMILAST; PREDNISONE;

ARTICLE; CHRONIC CUTANEOUS SARCOIDOSIS; CLINICAL ARTICLE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; NAUSEA; NERVOUSNESS; PRIORITY JOURNAL; RELAPSE; SARCOIDOSIS; SARCOIDOSIS ACTIVITY AND SEVERITY INDEX; SCORING SYSTEM; SIDE EFFECT; SKIN INDURATION;

FEMALE; HUMANS; MALE; PHOSPHODIESTERASE 4 INHIBITORS; SARCOIDOSIS; SEVERITY OF ILLNESS INDEX; SKIN DISEASES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84857405771     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2011.301     Document Type: Article

References (5)

1. Park MK, Fontana JR Jr, Babaali H, et al. Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2009;26(2):121-131.
2. Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase- 4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159(4):842-855.
3. Baughman RP, Judson MA, Teirstein A, et al. Chronic facial sarcoidosis including lupus pernio: clinical description and proposed scoring systems. Am J Clin Dermatol. 2008;9(3):155-161. (Pubitemid 351572057)
4. Baughman RP, Judson MA, Teirstein AS, Moller DR, Lower EE. Thalidomide for chronic sarcoidosis. Chest. 2002;122(1):227-232. (Pubitemid 34754167)
5. Stagaki E, Mountford WK, Lackland DT, Judson MA. The treatment of lupus pernio: results of 116 treatment courses in 54 patients. Chest. 2009;135(2):468-476.